Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264)

• ClinicalTrials.gov Identifier: NCT04152499
• Recruitment Status: Recruiting
• First Posted: November 5, 2019
• Last Update Posted: December 1, 2022
• Sponsor: Klus Pharma Inc.
• Information provided by (Responsible Party): Klus Pharma Inc.

Study Description

Brief Summary:

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types:

1. Triple negative breast cancer
2. Epithelial ovarian cancer
3. Non-small cell lung cancer
4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma
5. Small cell lung cancer
6. HR+/ HER2-breast cancer
7. Head and neck squamous cell carcinoma
8. Endometrial carcinoma
9. Urothelial carcinoma

Condition or disease	Intervention/treatment	Phase
Epithelial Ovarian Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Urothelial Carcinoma; Non-Small Cell Lung Cancer; Small-Cell Lung Cancer; Endometrial Carcinoma; Head and Neck Squamous Cell Carcinoma; Breast Cancer	Drug: SKB264	Phase 1; Phase 2

Detailed Description:

This is an open label, Phase I-II, first in human (FIH) study for SKB264 as monotherapy in patients who have locally advanced unresectable or metastatic solid tumor that is refractory to all standard therapies. TROP2 (trophoblast antigen 2) assessments will not be performed prior to enrollment but it will be assessed retrospectively. Confirmation of TROP2 (trophoblast antigen 2) expression by immunohistology or other means is not required, but the Sponsor will request fresh tumor biopsy or tissue specimens from archived materials for determination of TROP2 (trophoblast antigen 2) expression retrospectively. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy whose tumor is refractory to standard therapies. Patients will receive study drug as a single IV infusion at the prescribed dose level at each administration. Cycles will continue until disease progression or unacceptable toxicity. The study is divided into 2 parts (Phase I and Phase II).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 430 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
• Actual Study Start Date: February 28, 2020
• Estimated Primary Completion Date: November 2024
• Estimated Study Completion Date: December 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: Phase I: Dose Escalation; Five dose levels have been selected for evaluation in the Phase I part of the study: 2, 4, 6, 9, and 12 mg/kg of SKB264	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Triple Negative Breast cancer; Histologically documented or cytologically , incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Epithelial ovarian cancer; Histologically documented or cytologically , incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Non-Small Cell Lung Cancer; Histologically documented or cytologically, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Gastric Adenocarcinoma or gastroesophageal junction adenocarcinoma; Histologically or cytologically documented, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Extensive-stage small Cell Lung Cancer; Histologically documented or cytologically, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: HR+/ HER2- breast cancer; Histologically documented or cytologically, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Head and neck squamous cell carcinoma; Histologically documented or cytologically , incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Endometrial carcinoma; Histologically documented or cytologically , incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Urothelial carcinoma; Histologically or cytologically documented, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II:EGFR wild-type NSCLC; Histologically or cytologically documented, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Outcome Measures

Primary Outcome Measures :

1. Phase I: Maximum Tolerated Dose (MTD) and Recommended Doses for Expansion (RDEs) [ Time Frame: Assess up to 12 months ]
   To determine the maximum tolerated dose (MTD) and/or recommended doses for expansion (RDEs). RDEs will not exceed MTD.
2. Phase II: Objective Response Rate (ORR) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months ]
   To evaluate the objective response rate (ORR) [Complete Response (CR) + Partial Response (PR)] of SKB264 when administered intravenously (IV) as monotherapy at the RDEs to patients with metastatic or locally advanced unresectable tumors.

Secondary Outcome Measures :

1. Phase I: Dose Limiting Toxicities (DLTs) [ Time Frame: Day 28 days after first infusion of study drug ]
   To determine the dose limiting toxicities (DLTs) of SKB264 when administered IV twice (on Days 1 and 15) every 2 weeks in 4 weeks (28 days) cycles as monotherapy to patients with metastatic or locally advanced unresectable tumors.
2. Phase I: Overall safety and tolerability profile [ Time Frame: from the date of informed consent until 30 days after last infusion of study drug or begin a new anti cancer therapy, whichever occurs first ]
   Percentage of patients with adverse events (AEs), serious adverse events (SAEs), AEs with Grade ≥ 3 per NCI CTCAE v5.0, adverse events of Special Interest (AESI) and AEs related to study drug.
3. Phase I: Preliminary efficacy based on ORR (Objective Response Rate) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months ]
   ORR (Objective Response Rate) as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, which will be complete response (CR) + partial response (PR)
4. Phase I: Preliminary efficacy based on DOR(Duration of Response) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months ]
   To evaluate preliminary efficacy in patients treated with SKB264 as monotherapy based on DOR(Duration of Response).
5. Phase I: Preliminary efficacy based on PFS(Progression-Free Survival) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months ]
   To evaluate preliminary efficacy in patients treated with SKB264 as monotherapy based on PFS(Progression-Free Survival).
6. Phase I: Preliminary efficacy based on OS(Overall Survival) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months ]
   To evaluate preliminary efficacy in patients treated with SKB264 as monotherapy based on OS(Overall Survival)
7. Phase I: Percentage of patients with ADA formation to SKB264. [ Time Frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months ]
   To assess the incidence of anti-drug antibody (ADA) formation to SKB264.
8. Phase I: PK parameters for SKB264-ADC, SKB264 TAB, and free KL610023 payload. [ Time Frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months ]
   To characterize the PK of SKB264-ADC, SKB264 TAB, and free KL610023 payload, such as Cmax
9. Phase II: Overall safety and tolerability profile [ Time Frame: from the date of informed consent until 30 days after last infusion of study drug or begin a new anti cancer therapy, whichever occurs first ]
   Percentage of patients with adverse events (AEs), serious adverse events (SAEs), AEs with Grade ≥ 3 per NCI CTCAE v5.0, adverse events of Special Interest (AESI) and AEs related to study drug.
10. Phase II: Efficacy based on DOR (Duration of Response) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months. ]
    To evaluate efficacy in patients treated with SKB264 as monotherapy based on DOR(Duration of Response)
11. Phase II: Efficacy based on PFS (Progression-Free Survival) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months. ]
    To evaluate efficacy in patients treated with SKB264 as monotherapy based on PFS (Progression-Free Survival)
12. Phase II: Efficacy based on OS (Overall Survival) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months. ]
    To evaluate efficacy in patients treated with SKB264 as monotherapy based on OS (Overall Survival)
13. Phase II: Percentage of patients with ADA formation to SKB264. [ Time Frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months ]
    To obtain Percentage of patients with ADA formation to SKB264.
14. Phase II: PK parameters for SKB264-ADC, SKB264 TAB, and free KL610023 payload [ Time Frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months ]
    To characterize the PK of SKB264-ADC, SKB264 TAB, and free KL610023 payload, such as half life
15. Phase II: Levels of TROP2 expression in tumor tissue [ Time Frame: Screening and End of Treatment(EOT), approximately 12 months ]
    To assess levels of TROP2 expression in tumor tissue and correlation of those levels with responses and toxicity.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Diagnosis and Main Criteria for Inclusion:

Inclusion Criteria:

Patients must meet the following criteria for inclusion into the study:

Phase I:

1. Patients must be able to provide documented voluntary informed consent.
2. Male or female patient aged 18-75 years.

3. Histologically documented, incurable, locally advanced or metastatic epithelial origin malignant cancer, priority to include but not limited to the following tumor types:

   Breast cancer Ovarian epithelial cancer Non-small cell lung cancer Gastric adenocarcinoma Small cell lung cancer Urothelial carcinoma Note: Confirmation of TROP2 expression by immunohistology or other means is not required, but the Sponsor will request tissue specimens from fresh or archived materials for determination of TROP2 expression.

4. Measurable disease by CT/MRI during dose escalation.
5. Patients should have an unresectable locally advanced or metastatic solid tumor that is refractory to standard therapies, or have no standard therapies, or standard treatment is not applicable at this stage.
6. Granulocyte count ≥ 1.5×109/L, platelet count ≥ 100×109/L, and hemoglobin ≥ 9 g/dL.
7. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5×ULN.
8. Serum bilirubin ≤ 1.5 mg/dL (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 ×ULN may be enrolled)., aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN).
9. Creatinine clearance ≥ 50 mL/min calculated by Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration, or Modification of Diet in Renal Disease formulas. Note that 24 hour urine collection is not required but is allowed.
10. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.

11. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception during study treatment. Female and male patient treated with SKB264 should continue contraception use for 7 months after the last dose. Such methods include combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation together with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.

    • Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drug. The same rules are valid for male patients involved in this clinical trial if they have a partner of childbirth potential. Male patients must always use a condom.
    • Women are excluded from birth control if they had had tubal ligation or a hysterectomy.
12. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
13. Expected survival ≥ 3 months.

Phase II:

1. Patients must be able to provide documented voluntary informed consent.
2. Male or female patient aged ≥ 18 years.

3. Histologically or cytologically documented, incurable, locally advanced, recurrent or metastatic cancer, priority to include but not limited to the following tumor types (the sponsor will add or remove indications based on real-time study results):

   Triple negative breast cancer Epithelial ovarian cancer Non-small cell lung cancer (For Cohort 3B, only EGFR wild-type NSCLC will be enrolled) Gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (gastroesophageal junction adenocarcinoma is defined as tumor with center located within 5cm below/above the anatomical esophagogastric junction per Siewert classification system) Small cell lung cancer HR+/ HER2- breast cancer Head and neck squamous cell carcinoma (including primary tumor location of oropharynx, oral cavity, hypopharynx, or larynx. Other primary tumor sites of HNSCC, including nasopharynx (any histology) or unknown primary tumor are not eligible) Endometrial carcinoma (including carcinosarcoma, but except sarcoma and neuroendocrine endometrial carcinoma) Urothelial carcinoma (including urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra, patients with mixed histology are eligible provided urothelial component > 50% and plasmacytoid component<10% (Pathology will be locally assessed), patients whose tumors contain any neuroendocrine component are not eligible) Note: Confirmation of TROP2 expression by immunohistology or other means is not required, but the Sponsor will request tissue specimens from fresh or archived materials for determination of Trop-2 expression.

4. Measurable disease by CT/MRI.

5. For Cohort 1, 2, 3A, patients should have an unresectable locally advanced or metastatic solid tumor that is refractory to standard therapies, or have no standard therapies, or standard treatment is not applicable at this stage. For other cohorts, prior lines of therapy as below:

   Cohort 3B: EGFR wild-type NSCLC: Patients have received platinum-containing chemotherapy in combination with anti-PD-1/L1 monoclonal antibodies as the only prior line of therapy; Prior neoadjuvant and/or adjuvant system therapy/ radical chemoradiotherapy would be counted as a line of therapy if the patient progressed to unresectable locally advanced, recurrent or metastatic disease during or within 6 months of completing neoadjuvant or adjuvant therapy.

   Cohort 4: GC or GEJC: Patients who have been treated with only one prior therapy of chemotherapy and anti-PD-1/L1 monoclonal antibodies therapy and progressed during or after treatment. Prior neoadjuvant and/or adjuvant system therapy would be counted as a line of therapy if the patient progressed to unresectable locally advanced, recurrent or metastatic disease during or within 6 months of completing neoadjuvant or adjuvant therapy.

   Cohort 5: Second-line ES-SCLC: Patients who must have progressed on or after treatment with an anti-PD-1/L1 monoclonal antibodies administrated as part of first-line platinum-based systemic therapy for ES-SCLC. Previously treated limited stage SCLC will not be eligible.

   Cohort 6: HR+/ HER2-BC : Patients who have received previously at least two and no more than four lines of chemotherapy for unresectable locally advanced or metastatic disease with at least one taxane-containing in any setting. Prior neoadjuvant and/or adjuvant chemotherapy would be counted as a line of therapy if the patients progressed to unresectable locally advanced, recurrent or metastatic disease during or within 12 months of completing neoadjuvant or adjuvant therapy. Patients should also have previously presented a progression on anticancer hormonal therapy with a CDK 4/6 inhibitor and/ or a relapse during or after adjuvant endocrine therapy combined with an approved CDK4/6 inhibitor in this setting. Note: 1) Patients with HR+/HER2-BC and visceral crisis will be excluded. 2) For patients who have known BRCA mutation and HR+/HER2-BC, prior PARP inhibitor is required before enrolled in this study (where available and not medically contraindicated). 3) For patients with unknown BRCA status, prior PARP inhibitor is not required. 4) Patients who previously received therapy with an anti- HER2 ADC (T-Dxd) for HER2 low expressing tumors are eligible and this therapy will count as one chemotherapy line for unresectable locally advanced or metastatic disease.

   Cohort 7: HNSCC: Patients who have been previously treated with therapy of anti-PD-1/L1 monoclonal antibodies (either as a single-agent or in combination with platinum-based chemotherapy) as first-line treatment in recurrent/metastatic (R/M) setting and progressed during or after treatment. Prior definitive/multimodal therapy for locally advanced (LA) HNSCC that included anti-PD-1/PD-L1 monoclonal antibodies and platinum therapy would be counted as a line of therapy if the patient progressed during or within 6 months of completing definitive therapy.

   Cohort 8: Endometrial cancer: Patients who have previously failed with first-line platinum-based chemotherapy; patients with microsatellite stability/non-mismatch repair deficiency (MSS/pMMR) endometrial carcinoma must have received prior platinum-based therapy and progressed during or after treatment. Patients with known high microsatellite instability/mismatch repair deficiency (MSI-H/dMMR) endometrial carcinoma must have received prior platinum-based therapy and anti-PD-1/L1 monoclonal antibodies therapy and progressed during or after treatment. Prior neoadjuvant/adjuvant chemotherapy would be counted as a line of therapy if the patient progressed to unresectable locally advanced, recurrent or metastatic disease during or within 12 months of completing neoadjuvant or adjuvant therapy. Note: 1) If anti-PD-1/L1 monoclonal antibodies therapy is not approved for second-line treatment for MSI-H/dMMR endometrial cancer patients in certain regions, prior treatment with anti-PD-1/L1 monoclonal antibodies is not required. 2) If MMR/MSI status is unknown, patients who have been only treated with platinum based therapy is acceptable.

   Cohort 9: UC: Patients who have failed with prior first-line platinum-based therapy and received prior anti-PD-1/L1 monoclonal antibodies therapy and progressed during or after the latest treatment. Prior neoadjuvant/adjuvant system therapy would be counted as a line of therapy if the patient progressed to unresectable locally advanced, recurrent or metastatic disease during or within 12 months after completing neoadjuvant or adjuvant therapy.

6. Granulocyte count ≥ 1.5×109/L, platelet count ≥ 100×109/L, and hemoglobin ≥ 9 g/dL.
7. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5×ULN.
8. Serum bilirubin ≤ 1.5 mg/dL (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 ×ULN may be enrolled), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN).
9. Creatinine clearance ≥ 50 mL/min calculated by Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed.
10. ECOG Performance Status 0 or 1.

11. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception during study treatment. Female and male patient treated with SKB264 should continue contraception use for 6 months after the last dose. Such methods include combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation together with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.

    • Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drug. The same rules are valid for male patients involved in this clinical trial if they have a partner of childbirth potential. Male patients must always use a condom.
    • Women are excluded from birth control if they had had tubal ligation or a hysterectomy.
12. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo. Note: Subjects with endocrine AE of any grade are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.
13. Expected survival ≥ 3 months.

Exclusion Criteria:

Patients that meet the following criteria will be excluded from entry into the study:

Phase I:

1. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
2. Symptomatic brain metastases or any radiation or surgery for brain metastases within 1 months of first infusion of study drug.
3. Subjects with second primary cancers (except for cured in situ non-melanoma skin cancer and in situ cervical cancer with no relapse in the last 3 years).
4. Require supplemental oxygen for daily activities.
5. Documented Grade ≥ 2 peripheral neuropathy.
6. History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, corneal disease that prevents/delays corneal healing, macular degeneration.
7. Subjects previously treated with TROP 2 targeted therapies.
8. Any standard cancer therapy (e.g. chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment, or therapy with traditional Chinese medicines approved for anti-tumor treatment, etc.) within 4 weeks or five half-lives, whichever is shorter, of first infusion of study drug.
9. Any experimental therapy within 4 weeks or five half-lives, whichever is shorter, of first infusion of study drug.
10. Any major surgical procedure within 4 weeks of first infusion of study drug.
11. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis.
12. Have known prior positive test results or medical history for human immunodeficiency virus.
13. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) or diabetes (HbA1c ≥ 9.0%).
14. Subjects who require use of strong inhibitors or inducers of CYP3A4 at least 14 days prior to and throughout Study. Use of strong inhibitors or inducers of CYP3A4 is not allowed in this study. List of representative examples of strong inhibitors or inducers of CYP3A4 is provided in Appendix III.
15. Pregnancy or lactation.
16. Left ventricular ejection fraction < 45% determined by echocardiogram or multiple gated acquisition scan.
17. Resting QTc > 480 msec at baseline.
18. Ascites requiring paracentesis ≥1 per week.
19. Symptomatic pleural effusion (< 90% oxygen saturation).
20. Subjects with non-infectious interstitial lung diseases (ILD) or medical history of pneumonia requiring steroid treatments; severe pulmonary dysfunction caused by lung diseases.
21. New diagnosed thromboembolic events that requires therapeutic intervention over the last 6 months (patients with stable control of lower limb deep venous thrombosis are allowed).
22. The investigator considers other situations that patients are not appropriate to participate in this trial.

Phase II:

1. Any patient who was treated in the Phase I part of this study.
2. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
3. Symptomatic brain metastases or any radiation or surgery for brain metastases within 1 months of first infusion of study drug.
4. Patients with active second primary cancers (except for cured in situ non-melanoma skin cancer and in situ cervical cancer with no relapse in the last 3 years, or other malignant cancers that have been cured and no evidence of recurrence).
5. Require supplemental oxygen for daily activities.
6. Documented Grade ≥ 2 peripheral neuropathy.
7. History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, corneal disease that prevents/delays corneal healing, macular degeneration.
8. Patients previously treated with TROP 2 targeted therapies or topoisomerase I-containing antibody drug conjugates at any time for early stage or metastatic disease.
9. Any standard cancer therapy (e.g. chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment, or therapy with traditional Chinese medicines approved for anti-tumor treatment, etc.) within 4 weeks or 5 half-lives, whichever is shorter, of first infusion of study drug.
10. Any experimental therapy within 4 weeks or 5 half-lives, whichever is shorter, of first infusion of study drug.
11. Any major surgical procedure within 4 weeks of first infusion of study drug.
12. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis.
13. Have known prior positive test results or medical history for human immunodeficiency virus.
14. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) or diabetes (HbA1c ≥ 9.0%).
15. Subjects who require use of strong inhibitors or inducers of CYP3A4 at least 14 days prior to and throughout Study. Use of strong inhibitors or inducers of CYP3A4 is not allowed in this Study. List of representative examples of strong inhibitors or inducers of CYP3A4 is provided in Appendix III.
16. Pregnancy or lactation.
17. Left ventricular ejection fraction < 45% determined by echocardiogram or multiple gated acquisition scan.
18. Resting QTcF > 480 msec at baseline.
19. Ascites requiring paracentesis >1 per week.
20. Symptomatic pleural effusion (< 90% oxygen saturation).
21. History of interstitial lung diseases (ILD) or non-infectious pneumonitis requiring steroid treatments; severe pulmonary dysfunction caused by lung diseases.
22. New diagnosed thromboembolic events that requires therapeutic intervention over the last 6 months (patients with stable control of lower limb deep venous thrombosis are allowed).
23. The investigator considers other situations that patients are not appropriate to participate in this trial.

Contacts and Locations

Contacts

Contact: Study Manager; +1 416-471-1960; gurj@kelun.com

Locations

United States, California

University of California Los Angeles; Recruiting

Los Angeles, California, United States, 90404

Contact: Zev Wainberg

United States, District of Columbia

Georgetown University; Withdrawn

Washington, District of Columbia, United States, 20057

United States, Florida

Florida Cancer Specialists and Research Institute; Recruiting

Sarasota, Florida, United States, 34232

Contact: Judy Wang

United States, Massachusetts

Beth Israel Deaconess Medical Center; Withdrawn

Boston, Massachusetts, United States, 02215

United States, Michigan

START MidWest; Recruiting

Grand Rapids, Michigan, United States, 49546

Contact: Manish Sharma

United States, Oklahoma

The University of Oklahoma Health Sciences Center; Active, not recruiting

Oklahoma City, Oklahoma, United States, 73104

United States, Oregon

Providence Cancer Institute, Franz Clinic; Recruiting

Portland, Oregon, United States, 97213

Contact: Rachel Sanborn

United States, Texas

Mary Crowley Cancer Research; Terminated

Dallas, Texas, United States, 75230

MD Anderson Cancer Center; Recruiting

Houston, Texas, United States, 77030

Contact: Jordie Rodon

United States, Virginia

Virginia Cancer Specialists; Recruiting

Fairfax, Virginia, United States, 22031

Contact: Alexander Spira

China, Anhui

The Second Hospital of Anhui Medical University; Recruiting

Hefei, Anhui, China

Contact: Zhendong Chen

China, Chongqing

Chongqing University Cancer Hosptital; Not yet recruiting

Chongqing, Chongqing, China

Contact: Yongsheng Li

China, Fujian

The First Affiliated Hospital Of Xiamen University; Recruiting

Xiamen, Fujian, China

Contact: Yanjun Mi

China, Guangzhou

Sun Yat-sen University Cancer Center; Recruiting

Guangzhou, Guangzhou, China

Contact: Li Zhang

China, Hangzhou

Zhejiang Cancer Hospital; Recruiting

Gongshu, Hangzhou, China

Contact: Xiaozhong Chen

China, Henan

The First Affiliated Hospital of Zhengzhou University; Recruiting

Zhengzhou, Henan, China

Contact: Xingya Li

China, Hubei

Wuhan Union Hospital of China; Not yet recruiting

Wuhan, Hubei, China

Contact: Kunyu Yang

China, Hunan

Hunan Cancer Hospital; Recruiting

Changsha, Hunan, China

Contact: Yongzhong Luo

China, Shandong

Shandong Cancer Hospital; Recruiting

Jinan, Shandong, China

Contact: Bo Liu

China, Sichuan

West China Hospital of Sichuan University; Recruiting

Chengdu, Sichuan, China

Contact: Shuang Zhang

China, Wuhan

Hubei Cancer Hospital; Recruiting

Hongshan, Wuhan, China

Contact: Huiting Xu

China, Zhejiang

The First Affiliated Hospital, Zhejiang University School of Medicine; Recruiting

Hangzhou, Zhejiang, China

Contact: Nong Xu

Zhejiang Cancer Hospital; Recruiting

Hangzhou, Zhejiang, China

Contact: Yun Fan

ZHEJIANG University School of Medical SIR RUN RUN SHAW Hospital; Not yet recruiting

Hangzhou, Zhejiang, China

Contact: Xian Wang

China

Beijing Cancer Hospital; Recruiting

Beijing, China

Contact: Yunong Gao

Beijing Cancer Hospital; Not yet recruiting

Beijing, China

Contact: Jun Zhao

Beijing Chao-Yang Hospital, Capital Medical University; Not yet recruiting

Beijing, China

Contact: Guangyu An An

Chinese PLA General Hospital (301 Hospital); Recruiting

Beijing, China

Contact: Weihong Zhao

Jilin Cancer Hospital; Recruiting

Changchun, China

Contact: Ying Cheng

Hunan Cancer Hospital; Recruiting

Changsha, China

Contact: Quchang Ouyang

Sichuan Cancer Hospital; Recruiting

Chengdu, China

Contact: Wenxiu Yao

Chongqing University Cancer Hospital; Not yet recruiting

Chongqing, China

Contact: Dong Wang

The Second Hospital of Dalian Medical University; Recruiting

Dalian, China

Contact: Kui Jiang

Sun Yat-Sen Memorial Hospital , Sun Yat-sen University; Recruiting

Guangzhou, China

Contact: Ying Wang

Harbin Medical University Cancer Hospital; Recruiting

Harbin, China

Contact: Ge Lou

Hunan Cancer Hospital; Recruiting

Hunan, China

Contact: Keqiang Zhang

Jiangxi Cancer Hospital; Not yet recruiting

Nanchang, China

Contact: Jingao Li

The First Affiliated Hospital of Nanchang University; Not yet recruiting

Nanchang, China

Contact: Longhua Sun

Jiangsu Province Hospital; Recruiting

Nanjing, China

Contact: Yongmei Yin

Shandong Cancer Hospital; Recruiting

Shandong, China

Contact: Lihua Song

Fudan University Shanghai Cancer Center; Not yet recruiting

Shanghai, China

Contact: Dingwei Ye

Shanghai East Hospital; Recruiting

Shanghai, China

Contact: Jin Li, MD

Principal Investigator: Jin Li, MD

Zhongshan Hospital, Fudan University; Recruiting

Shanghai, China

Contact: Tianshu Liu

Liaoning Cancer Hospital; Recruiting

Shenyang, China

Contact: Danbo Wang

The First Hospital of China Medical University; Recruiting

Shenyang, China

Contact: Yunpeng Liu

The Fourth Hospital of Hebei Medical University; Recruiting

Shijiazhuang, China

Contact: Cuizhi Geng

Shanxi Provincial Cancer Hospital; Not yet recruiting

Taiyuan, China

Contact: Xia Song

Tianjin Cancer Hospital; Recruiting

Tianjin, China

Contact: Zhongsheng Tong

Tianjin Medical University Cancer; Not yet recruiting

Tianjin, China

Contact: Ke Wang

Weifang People's Hospital; Recruiting

Weifang, China

Contact: Guohua Yu

Hubei Cancer Hospital; Recruiting

Wuhan, China

Contact: Xinhong Wu

Wuhan Union Hospital of China; Not yet recruiting

Wuhan, China

Contact: Xiaoping Zhang

Zhongnan Hospital of Wuhan University; Not yet recruiting

Wuhan, China

Contact: Qiu Hui

The First Affiliated Hospital of Xi'an Jiaotong University; Recruiting

Xi'an, China

Contact: Ruifang An

Xuzhou Central Hospital; Recruiting

Xuzhou, China

Contact: Xiang Wang

Henan Cancer Hospital; Recruiting

Zhengzhou, China

Contact: Min Yan

Sponsors and Collaborators

Klus Pharma Inc.

Investigators

• Study Chair: Jordi Rodon Ahnert, MD, PhD; M.D. Anderson Cancer Center

More Information

• Responsible Party: Klus Pharma Inc.
• ClinicalTrials.gov Identifier: NCT04152499
• Other Study ID Numbers: KL264-01
• First Posted: November 5, 2019
• Last Update Posted: December 1, 2022
• Last Verified: November 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Klus Pharma Inc.:

TROP2, ADC

Additional relevant MeSH terms:

Carcinoma; Lung Neoplasms; Adenocarcinoma; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Carcinoma, Squamous Cell; Ovarian Neoplasms; Endocrine Gland Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Endocrine System Diseases; Gonadal Disorders; Head and Neck Neoplasms; Uterine Neoplasms; Uterine Diseases